Longitudinal comparison of combination antimalarial therapies in Ugandan children: evaluation of safety, tolerability and efficacy
| ISRCTN | ISRCTN37517549 |
|---|---|
| DOI | https://doi.org/10.1186/ISRCTN37517549 |
| Secondary identifying numbers | N/A |
- Submission date
- 16/05/2005
- Registration date
- 10/06/2005
- Last edited
- 09/08/2010
- Recruitment status
- No longer recruiting
- Overall study status
- Completed
- Condition category
- Infections and Infestations
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data
Plain English summary of protocol
Not provided at time of registration
Contact information
Prof Philip Rosenthal
Scientific
Scientific
San Francisco General Hopital
1001 Potrero Avenue
Building 30, Room 421
San Francisco
94110
United States of America
| Phone | +1 415 206 8845 |
|---|---|
| rosnthl@itsa.ucsf.edu |
Study information
| Study design | Randomised controlled trial |
|---|---|
| Primary study design | Interventional |
| Secondary study design | Randomised controlled trial |
| Study setting(s) | Other |
| Study type | Treatment |
| Scientific title | |
| Study objectives | We will test the hypothesis that the malaria treatment incidence density (number of treatments for malaria per time at risk) will differ among patients randomised to our three treatment groups (amodiaquine and sulfadoxine-pyrimethamine versus amodiaquine and artesunate versus artemether-lumefantrine). |
| Ethics approval(s) | Not provided at time of registration |
| Health condition(s) or problem(s) studied | Uncomplicated falciparum malaria |
| Intervention | Amodiaquine plus sulfadoxine-pyrimethamine versus amodiaquine plus artesunate versus artemether-lumefantrine |
| Intervention type | Drug |
| Pharmaceutical study type(s) | |
| Phase | Not Specified |
| Drug / device / biological / vaccine name(s) | Amodiaquine, sulfadoxine-pyrimethamine, artesunate, artemether-lumefantrine |
| Primary outcome measure | The effect of antimalarial drug therapy can be measured both in terms of drug efficacy (risk of true treatment failure) and post-treatment prophylactic effect (risk of new infection). To best reflect the overall impact of therapy, our primary outcome measurement will be the treatment incidence density (treatments per time at risk) for each treatment arm. To eliminate the period not influenced by study drugs, treatment count will exclude the first episode. Follow-up time will be from the first episode to the end of the study. Treatment count will include both first-line treatments with study drugs and second-line treatments with quinine following study drug failure. It will be assumed that participants will not be at risk for repeat therapy for 14 days after treatment with quinine, for which resistance has not been reported, so this time will be excluded when calculating total time at risk. |
| Secondary outcome measures | 1. Drug efficacy: We will examine the efficacy of the different treatment groups using each episode of malaria treated with a study drug as the unit of analysis. We will examine the risk for repeat treatment as a function of time. Short-term (14-day) assessments of treatment efficacy will provide a standard analysis that will be useful for comparisons with other studies. 1.1. Specific short-term outcomes to be assessed will include: 1.1.1. Clinical and parasitological outcome 1.1.2. Rates of fever and parasite clearance 1.1.3. Change in hemoglobin level from day zero to 14 1.1.4. Presence of gametocytes following treatment 1.1.5. Safety and tolerability of study medications 1.2. Long-term (beyond 14-day) outcomes will be: 1.2.1. Risk of recrudescence 1.2.2. Risk of new infection using Kaplan-Meier product limit estimates of risk at various time intervals (i.e. four, six, and eight weeks after initiation of therapy) In the analysis of long-term outcomes, molecular genotyping will be used to distinguish recrudescence (true treatment failure) from new infections. 2. Safety and tolerability: All adverse events will be catalogued based on their frequency, severity, and relationship to study medication using standardised protocols. These indices of safety and tolerability among treatment groups will be compared using each episode of malaria treated with a study drug as the unit of analysis. 3. Other long-term outcomes that will be assessed will include: 3.1. Incidence of asymptomatic parasitemia 3.2. Change in haemoglobin level over time 3.3. Perceived tolerability of study medications among subjects and care givers 3.4. Drug costs (comparison of total cost per patient) |
| Overall study start date | 01/11/2004 |
| Completion date | 20/04/2007 |
Eligibility
| Participant type(s) | Patient |
|---|---|
| Age group | Child |
| Lower age limit | 1 Year |
| Upper age limit | 10 Years |
| Sex | Both |
| Target number of participants | 601 |
| Key inclusion criteria | 1. Aged one to ten years 2. Agreement to come to the study clinic for any febrile episode or other illness 3. Agreement to avoid medications administered outside the study 4. Willingness of parents or guardians to provide informed consent |
| Key exclusion criteria | 1. History (obtained from the parent/guardian) of any known serious chronic disease requiring frequent medical care (e.g. Acquired Immune Deficiency Syndrome [AIDS], sickle cell disease, malignancy) 2. Intention to move from Kampala during the follow-up period 3. History (obtained from the parent/guardian) of serious side effects to study medications or sulfa drugs 4. Weight less than 10 kg 5. Severe malnutrition defined as weight-for-height or height-for-age Z-score less than -3 6. Homozygous haemoglobin SS (sickle cell) result by haemoglobin electrophoresis 7. Life-threatening screening laboratory value in the absence of malaria: 7.1. Absolute neutrophil count: less than 250/mm^3 7.2. Hemoglobin: less than 5.0 g/dl 7.3. Platelet count: less than 25,000/mm^3 7.4. Creatinine: less than two years: more than 1.5 mg/dl, more than two years: more than 2.0 mg/dl 7.5. Alanine transaminase (ALT): more than 15.0 x Upper Limit of Normal (ULN) 7.6. Bilirubin: more than 7.5 x ULN |
| Date of first enrolment | 01/11/2004 |
| Date of final enrolment | 20/04/2007 |
Locations
Countries of recruitment
- Uganda
- United States of America
Study participating centre
San Francisco General Hopital
San Francisco
94110
United States of America
94110
United States of America
Sponsor information
National Institutes of Health (NIH) - National Institute of Allergy and Infectious Diseases (NIAID) (USA)
Government
Government
c/o Philip E. Coyne, Jr., MD, MSPH
Program Officer, Parasitology and International Programs Branch
Division of Microbiology and Infectious Diseases
NIAID
6610 Rockledge Dr.
Room 5093, MSC 6604
Bethesda
20892-6603
United States of America
"ROR" |
https://ror.org/043z4tv69 |
|---|
Funders
Funder type
Government
The National Institute of Allergy and Infectious Diseases (NIAID) (USA)
No information available
Results and Publications
| Intention to publish date | |
|---|---|
| Individual participant data (IPD) Intention to share | No |
| IPD sharing plan summary | Not provided at time of registration |
| Publication and dissemination plan | Not provided at time of registration |
| IPD sharing plan |
Study outputs
| Output type | Details | Date created | Date added | Peer reviewed? | Patient-facing? |
|---|---|---|---|---|---|
| Results article | results | 23/05/2007 | Yes | No | |
| Results article | results | 30/07/2010 | Yes | No |
